GE Healthcare, the healthcare business of General Electric Company (NYSE:GE), received U.S. FDA approval of Clariscan™ injection for intravenous use. The approval expands the company’s portfolio for U.S. radiologists and patients. Clariscan has already been approved in over 55 countries internationally. It is the latest addition in an expanding range of imaging agents offering in the U.S. from GE.

Growing market

Kevin O’Neill, the CEO and President of Pharmaceutical Diagnostics at GE, expressed that the demand for contrast media has considerably surged over the past decade. The launch of Clariscan expands its clinical portfolio for U.S. radiologists, improving visualization to offer better patient care. Their customers depend on their first-rate supply network, high-quality products, and related services to support their work.

Sharing the same view, Dr. Lawrence N Tanenbaum, M.D., FACR said that the FDA’s approval of Clariscan adds to the portfolio of contrast media options offered in the U.S. As radiologists, they welcome this new choice.

Earlier in October, Theragnostics and GE Healthcare entered into an international commercial deal for a new PSMA PET/CT imaging agent. As per the deal, Theragnostics will look after the advancement of GalliProst, while GE Healthcare will handle all pre-approval commercial arrangements. Also, the company will look after commercial and distribution activities once the approval is received. Currently, prostate cancer marks as the fourth leading cancer type accounting for more than 1.2 million new cases globally in 2018.

GE Healthcare partnership with Theragnostics on GalliProst will provide important insights into prostate cancer. This partnership allows both parties use each other’s main areas of expertise to accelerate the advancement of GalliProst and eventually enhance patient care.

Greg Mullen, the CEO of Theragnostics, said that this deal is proof of the potential for their unique prostate cancer Gallium-68 diagnostic tracer, which can help the treatment of patients with prostate cancer. They are delighted to sign their second deal with GE Healthcare after their agreement in 2018 for a diagnostic tracer targeting imaging kidney function and scarring.